Rational approach to drug discovery for human schistosomiasis
Human schistosomiasis is a debilitating, life-threatening disease affecting more than 229 million people in as many as 78 countries. There is only one drug of choice effective against all three major species of Schistosoma, praziquantel (PZQ). However, as with many monotherapies, evidence for resist...
Main Authors: | Philip T. LoVerde, Sevan N. Alwan, Alexander B. Taylor, Jayce Rhodes, Frédéric D. Chevalier, Timothy JC. Anderson, Stanton F. McHardy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | International Journal for Parasitology: Drugs and Drug Resistance |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221132072100021X |
Similar Items
-
Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
by: Anastasia R. Rugel, et al.
Published: (2020-08-01) -
Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments
by: Katalin Toth, et al.
Published: (2023-04-01) -
Specific treatment of hepatosplenic schistosomiasis can increase T-lymphocyte reactivity
by: Maria Imaculada Muniz-Junqueira, et al.
Published: (1991-06-01) -
Treatment of schistosomiasis: gathering stones together
by: J. R. Lambertucci
Published: (1995-04-01) -
The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase
by: Livia Pica-Mattoccia, et al.
Published: (2006-10-01)